WO2001026701A2 - Partikuläres konstrukt zur verwendung in der transplantationsmedizin - Google Patents
Partikuläres konstrukt zur verwendung in der transplantationsmedizin Download PDFInfo
- Publication number
- WO2001026701A2 WO2001026701A2 PCT/DE2000/003658 DE0003658W WO0126701A2 WO 2001026701 A2 WO2001026701 A2 WO 2001026701A2 DE 0003658 W DE0003658 W DE 0003658W WO 0126701 A2 WO0126701 A2 WO 0126701A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- constructs
- construct
- polymer
- dispersion solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
Definitions
- the invention relates to the use of a biologically active particulate construct based on a spatial support structure made of at least one hardened biocompatible polymer, a plurality of cells of at least one human cell type being embedded in the support structure, a particulate construct which is particularly suitable for use, and a method for its manufacture.
- the skin has three main layers, which differ in their function. Starting from the surface The build-up begins with the epidermis. This is a multi-layered, horny squamous epithelium, in which the keratinocytes predominate with a share of approx. 75%. Mitotic processes only take place in the stratum basale, the lowest layer of the epidermis. It is firmly attached to the underlying basement membrane, an extracellular matrix.
- the dermis which consists of connective tissue, lies below the basement membrane. This is a combination of fibroblasts, intercellular substances and fat cells.
- the intercellular substances consist, for example, of collagen, fibronectm and elastin.
- the dermis serves to stabilize the skin and regulate the skin pressure.
- the keratinocytes differentiate in it.
- the subcutaneous tela closes the skin to the underlying structures, fascia, bones and / or muscles.
- the concept of creating an artificial skin is based on the technology of flat tissue constructs. These have a sandwich structure containing a flat substrate and a layer of cultivated, living body surface cells, in particular fibroblasts and / or keratocytes, adhering to the flat, non-living substrate.
- the body surface cells are not necessarily a cell assembly, as occurs in an organism.
- Flat tissue constructs are used to close and regenerate wounds, particularly burns.
- Flat tissue constructions of known construction are described, for example, in the literature references US-A 5,131,907, US-A 5,273,900 (a comprehensive background illustration of the technological context is given here), US-A 5,282,859, US-A 5,800,537 and US-A 5,888,248.
- Fibrin glue consists of two components, fibrmogen and thrombin, which causes the fibrmogen to cure enzymatically.
- the ready-to-use cell suspension is produced by first suspending the cells in the fibrmogen component and adding the thrombin immediately before the application. While this technology leads to improved growth of intact cells, it has other disadvantages.
- a particular disadvantage is that the cells have no protection against shear stresses and can be mechanically overloaded during application or when moving in the wound area.
- the level of proliferation-requiring signal substances, in particular the growth factors, in the area of the sprayed-on cells is rather low and the growth rate can therefore be improved.
- Reference W099 / 15637 describes particulate constructs for use, inter alia, known in transplantation medicine, which consist of a solid fibrin core and human cells arranged on the surface of the core.
- the fibrin is highly cross-linked.
- a disadvantage of these constructs is that cell growth and consequently tissue formation are essentially two-dimensional and the level of growth factors is comparatively low.
- the cells are not protected against shear loads due to their arrangement on the outside.
- this is disadvantageous already during the manufacture and preparation of the constructs. After all, such structures tend to clump together.
- the invention is based on the technical problem of specifying cells-containing constructs for transplantation medicine, which ensure a drafty and as complete as possible reconstruction of damaged skin areas and at the same time are simple to use.
- the invention teaches the use of a biologically active particulate construct based on a spatial support structure made of at least one hardened biocompatible polymer, wherein in the support structure a plurality of cells of at least one (preferably human) Cell type is embedded in transplant medicine.
- the concentration of growth factors within a particular construct is quite high due to the high cell density that can be achieved with contact inhibition not yet occurring.
- the cell density can be easily optimized in terms of production technology.
- the surrounding support structure protects the cells against shear stress.
- the application is very simple, since a dispersion containing the constructs only needs to be introduced into a wound, and without an immediate previous one
- the expression biologically active means, based on cells, that at least 20%, preferably at least 50%, most preferably at least 80%, based on the cell numbers, of the cells are capable of proliferation, measured for example by means of the MTS proliferation assay (CellTitre 96 AQueous One Solution Cell Proliferation assay, Promega).
- MTS proliferation assay CellTitre 96 AQueous One Solution Cell Proliferation assay, Promega.
- a particulate construct has a pronounced three-dimensional extension in contrast to flat constructs, which essentially extend in two spatial dimensions. In other words, it is a particle, the maximum extents of which do not differ significantly in the 3 spatial dimensions. Factors between the maximum extents in any two of the three spatial dimensions are less than 10, preferably less than 5, most preferably less than 2.
- Particulate constructs in particular have an essentially spherical outer shape (factors less than 1.2).
- Particulate constructs can be solid, hollow, or porous.
- massive means a porosity (open + closed porosity) of less than 5% by volume, measured for example by small-angle neutron scattering.
- a spatial support structure describes a supporting framework made of a solid material, which gives the particular construct its shape.
- the cells arranged in it are fixed and immobilized by the support structure.
- Biocompatible are polymers that are (human) contracted, ie do not cause immunological reactions of a (human) body or symptoms of intoxication. Biocompatible polymers can also be absorbed by a (human) organism and / or dissolved in body fluids.
- the biocompatible polymers are selected such that the support structure of a construct which has been introduced into a human skin lysate and has a support structure weight of 0.1 mg within a period of 0.1 to 20 days. preferably 1 to 10 days, most preferably 2 to 5 days, is completely degraded or dissolved.
- Transplantation medicine means in particular the medicine of skin replacement by constructs that form artificial skin tissue. Skin replacement may be necessary, for example, in the case of burn wounds or for closing other skin defect wounds (for example congenital skin defects and / or circulatory disorders), the defect wounds may also have arisen in the course of a medically necessary excision.
- Transplantation medicine in the sense of the invention also includes the replacement and / or supplementation of other types of tissue with suitable cells. This can be particularly useful if tissue has malfunctions. It is then possible to replace or supplement, for example, cells that do not have this malfunction.
- the expression of transplantation medicine also includes veterinary medical applications.
- the term "fully cured” encompasses both the crosslinking of polymer molecules and drying. Drying is the solidification of polymer compositions from a solution or dispersion (aqueous or organic) containing the composition, for example by expelling the solvent or segregating the composition from the solvent.
- the degree of crosslinking of the polymer is given by the relative proportion of crosslinked polymer molecules to the total number of polymer molecules (crosslinked + uncrosslinked).
- Physiologically active substances are substances that influence the metabolism of the organism and / or the cells of a construct. It is understood that such active ingredients are used in an effective dose.
- a construct has non-contact inhibited cells if at least 20%, preferably at least 50%, most preferably at least 70%, ideally 80% to 100%, of the cells in the construct are not contact inhibited.
- Autologous cells are cells from an organism, which are then implanted again in this organism.
- a polymer can be cured in a number of ways.
- the polymer can be gelled and thus solidified, for example by lowering the temperature compared to the temperature of the liquid polymer.
- solidification can take place by chemical reaction.
- the solidification can be carried out enzymatically. For the latter, the fibrmogen / thromb reaction is an example.
- a hardening reagent is a substance or a
- An uncured polymer is a liquid polymer.
- a cured polymer is a solidified polymer.
- a dispersion solution is a liquid phase, in which a second, immiscible or difficult to mix Liquid or a solid substance can be dispersed. Dispersion means that the dispersed phase practically does not aggregate.
- a dispersion solution can contain, for example, emulsifiers such as lecithin or Triton X100.
- a cell suspension essentially consists of isolated cells in a liquid phase, for example in uncured polymer and / or in medium.
- subconfluence is typically present at cell densities below 1.5 * 10 5 cells / cm 2 , in particular below 5 * 10 4 cells / cm 2 .
- dropping or dropleting means that drops form from a liquid phase above a dispersing solution, which practically do not disintegrate into smaller drops in the dispersing solution and are practically not disintegrated within them, but are kept intact only in suspension become.
- the support structure can contain a biocompatible polymer or several such polymers from the group consisting of "fibrin, collagen I, hyaluronic acid, collagen-glycosaminoglycan and chondroitin- ⁇ -sulfate", in particular consist thereof. These polymers are characterized by excellent human tolerance and good behavior in terms of absorption kinetics (Resorption of the support structure of a construct in a skin wound within 1 to 5 days).
- the polymer expediently has a degree of crosslinking of less than 30%, preferably less than 15%.
- the carrier structure contains a physiologically active substance or several such substances from the group consisting of "therapeutic substances, vitamins, vitamin derivatives, growth factors, glycocorticosteroids, steroids, antibiotics, antibacterial substances, antiviral substances, fungicides, cytostatics, tumor inhibitors , Enzymes, enzyme inhibitors, proteins, peptides, minerals, neurotransmitters, lipoprotems, glycoprotems, immunomodulators, immunoglobulms and fragments thereof, fatty acid derivatives, polysaccharides, anti-inflammatory substances, nucleic acids, polynucleotides and anesthetics ". Pain relief can be achieved locally in the wound area using anesthetics. Other substances in the group prevent inflammatory reactions. Growth factors also require the regeneration of the new tissue. In any case, it is essential that the active ingredient not inhibit the proliferation of the cell type used in the construct or even cause apoptosis.
- the human cell type is selected from the group "fibroblasts, fat cells, keratmocytes, chondrocytes, osteoplasts, endothelial cells, nerve cells, liver cells, pancreatic cells, spleen cells, kidney cells and muscle cells", autologous cells preferably being used. Fibroblasts, keratocytes and / or Fat cells are particularly suitable in the area of skin grafting. The other cell types are suitable in cases in which the corresponding tissue of a patient has functional disorders. The implantation of intact pancreatic cells, by means of which a lack of insulin production can be restored, may be mentioned merely as an example. It is also possible to work with autologous cells that have been repaired, for example, by genetic engineering.
- a construct which can be used according to the invention can be obtained, for example, by adding a suspension of isolated cells in a biocompatible polymer, optionally mixed with a reagent which cures the polymer, dispersing uncured particulate constructs into a dispersion solution and forming these constructs in the dispersion solution be hacked.
- constructs with particularly uniform dimensions are obtained.
- the diameter of the constructs obtained is typically in the range from 0.05 mm to 5 mm, preferably between 0.1 mm and 2 mm, and can be selected within the scope of the dropping technology.
- the spread in diameter is particularly small.
- the invention also relates to a construct which can be used particularly advantageously and which is obtainable by dropping a cell suspension together with a biocompatible polymer into a dispersion solution and curing the droplets formed in the dispersion solution.
- the polymer is preferably mixed with a hardening reagent, preferably an enzymatic hardening reagent, for example thrombin, immediately before being introduced into the dispersion solution.
- the dispersion solution is expediently not aqueous and advantageously has two (liquid) phases, the densities of the two phases being chosen such that the constructs cannot sediment beyond the phase boundary between the two phases.
- This has the effect that dripped uncured constructs cannot sink to the bottom of a vessel containing the dispersion solution, but in any case are kept in suspension in the region of the phase boundary.
- a magnetic stirrer can be used as an agitation element, for example, without the agitation element being able to mechanically damage the constructs.
- a third liquid phase can also be used, which is then arranged at the top and has a lower density than the constructs, uncured or hardened.
- constructs according to the invention are porous and medium, for example, therefore has access to the entire construct volume.
- the cultivation is also particularly unproblematic because the cells are mechanically protected. Highly efficient cultivation techniques can therefore be used (for example in stirred and / or fumigated bioreactors or columns), with the result that the time taken to produce an autologous construct is considerably reduced.
- constructs with different cell types for example fibroblasts and keratocytes, can be cultivated in a single reactor, separated only by a membrane, under the same conditions. Cultivation is advantageously carried out only as long as subconfluence is maintained. This also ensures that the cells are differentiated not in vitro but in vivo, which is particularly advantageous for the reconstruction of skin tissue, for example
- the invention also teaches a method for producing a biologically active particulate construct, wherein a suspension of a plurality of isolated human cells in a biocompatible polymer, forming uncured particulate constructs, is dripped into a dispersion solution, the uncured particulate constructs being cured in the dispersion solution and wherein the hardened particulate constructs are taken from the dispersion solution.
- (porous) solid spheres are obtained in the sense that the cells are distributed essentially uniformly in the construct volume.
- the uncured particulate constructs are preferably carried out Formed droplets from a capillary and then introduced into the dispersing solution.
- Anisotropic constructs can be achieved if uncured particulate constructs are produced by feeding a suspension containing isolated cells and a biocompatible polymer to a dropping device, the dropping device being provided with a central cell suspension capillary opening and a polymer cartridge arranged coaxially therewith. has pillar opening, wherein the suspension containing isolated cells and the polymer are simultaneously dripped from the cell suspension capillary opening and the polymer capillary opening to unhardened particular constructs and introduced into the dispersion solution, the unhardened particular constructs being hardened in the dispersing solution and the hardened particulate Constructs of the dispersion solution are taken.
- Hollow spheres are then obtained in the sense that the polymer forms a spherical shell in which the cells are arranged, the cells not being embedded in a polymer matrix.
- Such constructs are advantageous in terms of cell growth, since the exchange of self-generated growth factors is improved.
- a gas flow jacket be generated when dripping.
- an annular gas outlet opening coaxial with the capillary outlet opening can be provided in the area of a capillary outlet opening.
- the gas flow jacket requires uniform drop formation and can (instead of or in addition to that Volume flow from the Kapallarauslenfino réelle) can also be used to control the drop size and varied.
- a dropletization technology which is advantageous with regard to droplet formation and formation consists in that when dropletization occurs in a capillary, rotationally symmetrical vibrations m are generated in the liquid jet in the capillary and are superimposed on the liquid jet, the wavelength of the vibrations being greater than the circumference of the liquid jet without superposition of vibrations is.
- Unhardened and / or hardened constructs if appropriate after cultivation, preferably contain 10 4 to 10 6 cells per ml of construct volume.
- V79 firoblasts were grown in culture bottles in medium DMEM / F12 with 3% FCS.
- the cells were detached and separated after removal of the medium using a PBS / EDTA solution.
- the detached cells were then transferred to a centrifuge tube and 5 mm. centrifuged at 1000 rpm. The supernatant was discarded and the cells were taken up in 200 ⁇ l medium DMEM / F12 with HEPES and 3% FCS.
- game 2 In game 2
- Example 1 The cells obtained in Example 1 (seed density: 10 "to 10 6 cells e ml) were encapsulated as follows.
- 1 ml fibrinogen solution (TISSUCOL ® kit 1.0 from Immuno; 126-198 mg dry substance contain 80-120 mg human plasma protein fraction with 70 -110mg fibrinogen, 2-9mg plasma fibronectin, 10-50 U [1E corresponds to the activity contained in 1ml of fresh normal plasma] blood coagulation factor XIII and 0.02-0.08 mg plasminogen, rest: auxiliary substances NaCl, sodium citrate, aprotin, Glycine, heparin, triton, human albumin) was prepared according to the package insert (product version: June 1, 1999) 200 ⁇ l of the resuspended cells from example 1 were taken up in the fibrmogen solution and mixed well (total volume: 1.2 ml).
- thrombin L- Solution 1 ml thrombin L- Solution (TISSUCOL 0 kit from Immuno, product version: 01.06.1999) was prepared according to the package insert and mixed with 200 ⁇ l sterile water for injection (total volume: 1.2ml) Both solutions were mixed in different chambers of a double syringe it is placed directly adjacent to the exit nozzles of the chambers. By actuating the two syringe pistons (producing the same volume flows from the chambers), drops were generated, the two solutions merging in the area of the outlet nozzles. The drops were dropped into a dispersion solution.
- the dispersion solution consisted of Fluorinert 0 dielectrics FC40 from 3M (according to 3M data sheet in the version dated 03.01.1998 a primary perfluorocompound with 12 carbon atoms) and, layered over it, Miglyol 0 from H ls AG (T ⁇ glycerides from C8 to C12 Fatty acids).
- the resulting dispersion solution was used before use 20 mm. autoclaved at 121 ° C.
- the dispersing solution was in a beaker with angled Ruhr fish on a magnetic stirrer (200 - 500 rpm) and at room temperature. Then they were cured at room temperature with stirring.
- Fibroblasts were separated in the above manner and added to a collagen I solution.
- the solution was obtained by dissolving the collagen in medium using HC1 and then neutralizing with NaCl.
- the cell suspension obtained in this way was dripped from a simple syringe into the dispersion solution described above. After 16 hours at 37 ° C., solid constructs were obtained by gelling and further treated as described above.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT00984834T ATE260681T1 (de) | 1999-10-12 | 2000-10-12 | Partikuläres konstrukt zur verwendung in der transplantationsmedizin |
EP00984834A EP1231949B1 (de) | 1999-10-12 | 2000-10-12 | Partikuläres konstrukt zur verwendung in der transplantationsmedizin |
AU21482/01A AU2148201A (en) | 1999-10-12 | 2000-10-12 | Particulate construct for use in the transplantation field |
DE50005546T DE50005546D1 (de) | 1999-10-12 | 2000-10-12 | Partikuläres konstrukt zur verwendung in der transplantationsmedizin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19949290A DE19949290A1 (de) | 1999-10-12 | 1999-10-12 | Partikuläres Konstrukt zur Verwendung in der Transplantationsmedizin |
DE19949290.5 | 1999-10-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001026701A2 true WO2001026701A2 (de) | 2001-04-19 |
WO2001026701A3 WO2001026701A3 (de) | 2001-12-06 |
Family
ID=7925456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2000/003658 WO2001026701A2 (de) | 1999-10-12 | 2000-10-12 | Partikuläres konstrukt zur verwendung in der transplantationsmedizin |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1231949B1 (de) |
AT (1) | ATE260681T1 (de) |
AU (1) | AU2148201A (de) |
DE (2) | DE19949290A1 (de) |
WO (1) | WO2001026701A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144729B2 (en) * | 2000-09-01 | 2006-12-05 | Dfb Pharmaceuticals, Inc. | Methods and compositions for tissue regeneration |
KR100531922B1 (ko) * | 2003-12-23 | 2005-11-29 | 주식회사 셀론텍 | 연골치료제 조성물 및 그 사용방법 |
KR100702250B1 (ko) * | 2005-06-13 | 2007-04-03 | 세원셀론텍(주) | 피브린 혼합형 골절 유합용 반고형성 뼈세포 조성물 및이의 제조방법 |
KR100751690B1 (ko) * | 2005-06-13 | 2007-08-23 | 세원셀론텍(주) | 조골 세포와 생체 기질 성분의 혼합물을 이용한 골 생성용조성물 및 그 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0213908A2 (de) * | 1985-08-26 | 1987-03-11 | Hana Biologics, Inc. | Transplantierbares Kunstgewebe und Verfahren |
DE4438015A1 (de) * | 1994-10-25 | 1996-05-02 | Boehringer Mannheim Gmbh | Epithelzellenhaltiges Biomaterial und dessen Verwendung als Transplantat |
US5830507A (en) * | 1992-05-18 | 1998-11-03 | National Research Council Of Canada | Biotherapeutic cell-coated microspheres |
WO1999015637A1 (en) * | 1997-09-19 | 1999-04-01 | V.I. Technologies, Inc. | Fibrin microbeads and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0707498T3 (da) * | 1993-07-07 | 2003-10-20 | Smith & Nephew | Implanterbar protese, kit og indretning til fremstilling af samme |
DE19612998A1 (de) * | 1996-03-22 | 1997-09-25 | Dizg Deutsches Inst Fuer Zell | Zellschichten und Transportsystem für Zellschichten |
DE19632404A1 (de) * | 1996-08-02 | 1998-04-02 | Michael Dr Sittinger | Transplantierbare Knorpelgewebe mit immunsuppressiven Eigenschaften, Verahren zu ihrer Herstellung und Verwendung |
IT1293484B1 (it) * | 1997-06-11 | 1999-03-01 | Fidia Advanced Biopolymers Srl | Materiale biologico comprendente una efficiente coltura di cellule e una matrice tridimensionale biocompatibile e biodegradabile |
ES2175753T3 (es) * | 1997-06-27 | 2002-11-16 | Augustinus Bader | Injerto biosintetico y metodo para su produccion. |
DE19805673C2 (de) * | 1998-02-12 | 2002-09-26 | Wolfgang Quante | Verfahren und Kit zur Herstellung eines Knochenersatz- und Augmentationsmaterials |
KR20010072553A (ko) * | 1998-02-24 | 2001-07-31 | 나우톤 질 케이. | 살아있는 키메릭 피부 대체물 |
-
1999
- 1999-10-12 DE DE19949290A patent/DE19949290A1/de not_active Withdrawn
-
2000
- 2000-10-12 WO PCT/DE2000/003658 patent/WO2001026701A2/de active IP Right Grant
- 2000-10-12 DE DE50005546T patent/DE50005546D1/de not_active Expired - Lifetime
- 2000-10-12 EP EP00984834A patent/EP1231949B1/de not_active Expired - Lifetime
- 2000-10-12 AU AU21482/01A patent/AU2148201A/en not_active Abandoned
- 2000-10-12 AT AT00984834T patent/ATE260681T1/de not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0213908A2 (de) * | 1985-08-26 | 1987-03-11 | Hana Biologics, Inc. | Transplantierbares Kunstgewebe und Verfahren |
US5830507A (en) * | 1992-05-18 | 1998-11-03 | National Research Council Of Canada | Biotherapeutic cell-coated microspheres |
DE4438015A1 (de) * | 1994-10-25 | 1996-05-02 | Boehringer Mannheim Gmbh | Epithelzellenhaltiges Biomaterial und dessen Verwendung als Transplantat |
WO1999015637A1 (en) * | 1997-09-19 | 1999-04-01 | V.I. Technologies, Inc. | Fibrin microbeads and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1231949B1 (de) | 2004-03-03 |
WO2001026701A3 (de) | 2001-12-06 |
AU2148201A (en) | 2001-04-23 |
DE19949290A1 (de) | 2001-04-26 |
DE50005546D1 (de) | 2004-04-08 |
ATE260681T1 (de) | 2004-03-15 |
EP1231949A2 (de) | 2002-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69534083T2 (de) | Brustgewebetechnologie | |
EP2273997B1 (de) | Verfahren und zusammensetzung zur regeneration von gewebe mit hilfe von stamm- oder knochenmarkzellen | |
EP1633807B1 (de) | Matrix, zellimplantat, verfahren zu deren herstellung und deren verwendung | |
EP0406375B1 (de) | Alloplastisches implantat | |
DE69829662T2 (de) | Vorrichtung und verfahren zur wundbehandlung | |
DE19953771C1 (de) | Resorbierbares Knochen-Implantatmaterial sowie Verfahren zur Herstellung desselben | |
DE69531821T2 (de) | Mehrlagige alginatbeschichtungen von biologischen geweben für die transplantation | |
DE60204352T2 (de) | Haut/haar-äquivalent mit rekonstruierten papillen | |
CH657786A5 (de) | Verfahren zum einkapseln eines kernmaterials innerhalb einer semipermeablen membran. | |
WO2003015803A1 (de) | Zellzusammensetzungen zur behandlung von osteoarthrose, sowie verfahren zu deren herstellung | |
EP1289574B1 (de) | Verfahren zur kultivierung von knorpelersatz und biomatrix nach diesem verfahren hergestellt | |
DE3936568C2 (de) | Wirkstoffkomplex für die Herstellung von biologischen Teilen in Form von Organen für Lebewesen; Verfahren zum Herstellen desselben und seine Verwendung | |
EP3319652B1 (de) | Verfahren zur herstellung eines bioartifiziellen, primär azellulären konstrukts auf fibrinbasis und dieses konstrukt selbst | |
EP1517988A2 (de) | Verfahren und vorrichtung zur vermehrung und differenzierung von zellen in anwesenheit von wachstumsfaktoren und einer biologischen matrix oder trägerstruktur | |
WO2002048317A2 (de) | Verfahren und vorrichtung zur herstellung von biologischem gewebe in einer wachstumskammer | |
DE60120127T2 (de) | Injizierbare mikrokügelchen für den gewebeaufbau | |
EP1706157B1 (de) | Verfahren zur herstellung von bandscheibenzelltransplantaten und deren anwendung als transplantationsmaterial | |
EP1231949B1 (de) | Partikuläres konstrukt zur verwendung in der transplantationsmedizin | |
WO2004042038A1 (de) | Verfahren zur behandlung von erkranktem,degeneriertem oder geschädigtem gewebe unter verwendung von in vitro hergestelltem dreidimensionalem gewebe in kombination mit gewebezellen und/oder exogenen faktoren | |
EP1184040A1 (de) | Hautmatrix zur Abdeckung und Regenerierung verletzter Hautpartien sowie Verfahren zu ihrer Herstellung | |
EP0636033B1 (de) | Verfahren zur herstellung von wirkstoffkomplexen | |
EP1518569A1 (de) | Implantatmaterial für den Knochen-Knorpel-Ersatz | |
EP1905464B1 (de) | Implantat und Verfahren zu seiner Herstellung | |
DE10327879A1 (de) | Rekonstruierte dermale Papille | |
EP1338285A1 (de) | Plasmagel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000984834 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000984834 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000984834 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |